Hillgene Reached a Strategic Cooperation with HighthinkMed in Exploring One-Stop Whole-Process Innovative Service Mode for Cellular Therapy Products

Recently, Jiangsu Specoxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Specoxin Biopharmaceutical") and Beijing Hekinge Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Hekinge Pharmaceutical") held a strategic cooperation signing ceremony. Through this strategic cooperation, Specoxin Biopharmaceutical and Hekinge Pharmaceutical will make full use of their respective advantages, customer resources and professional team service capabilities to jointly promote the relevant businesses of both parties in the fields of customer drug clinical research, CMC and CDMO.

Specoxin Biopharmaceutical has built a nucleic acid platform dedicated to cell drugs, a suspended serum-free virus production platform and a fully enclosed cell process development platform, creating a highway for cell drugs from discovery to product delivery, and can provide personalized one-stop high-quality CDMO services for customers with different needs. Hekinge Pharmaceutical has a complete service system for clinical research of innovative drugs, rich clinical resources, and a professional, standardized and large-scale clinical research CRO service platform, especially in the field of clinical research of cell drugs.

This strategic cooperation will promote the establishment of a "CRO+CDMO" linkage service model. From clinical to CMC, the two parties will be connected in an orderly manner and work closely together. Biopharmaceutical enterprise customers will be able to experience the full process service more efficiently and in a one-stop manner, further improving the efficiency of innovative drug research and development.

Sun Liying, CSO of Hekinger, visited Suzhou and participated in the Cell and Gene Therapy Industrialization Development Summit and the first anniversary celebration of the launch of the Spectrum Bio-Brand. Hekinger Pharmaceuticals also participated in the strategic signing ceremony between Spectrum Bio-Brands and Hekinger Pharmaceuticals.

About Hekinger Pharmaceuticals

Hekinger Pharmaceuticals is a contract research organization (CRO) that specializes in providing Phase I-IV clinical research and related technical services to pharmaceutical companies, medical device companies and new drug research institutions. The company was founded in 2006. After 16 years of hard work in the clinical research CRO industry, it has established a technical team of "altruism, ingenuity, professionalism and efficiency". It has provided nearly 700 drug clinical research technical services, audits, CRC and related consulting services to more than 400 pharmaceutical companies and research institutions. The company focuses on clinical research technical services for innovative drugs in China and the United States and technical services in the field of innovation. It is committed to ensuring data quality, ensuring progress plans, and protecting information security. It provides customers with one-stop Sino-US dual-reporting technical services and MAH overall solutions. Through the development strategy of business and capital dual-wheel drive, it will work tirelessly for customers' new drugs to be quickly launched, realize customer value and employee value at the same time, and strive for a healthy China.

About Spectrum Bio

Headquartered in Wuzhong District, Suzhou City, on the beautiful shore of Taihu Lake, it has Suzhou headquarters (10,000 square meters of GMP plant and R&D center), Shenzhen and Shanghai bases, and has initially formed a nationwide production base network layout; the North Carolina base in the United States is also under construction, and the global layout is being carried out simultaneously. It has built a nucleic acid platform dedicated to cell drugs, a suspended serum-free virus production platform, a fully enclosed cell process development platform and a quality control and detection technology platform, creating a highway from discovery to product delivery of cell drugs. The platform has supported multiple partners to successfully incubate a number of CAR-T, TCR-T, stem cells and other drugs. Spectrum Biopharma is committed to enabling more projects to reach the next milestone earlier and faster, bringing more cellular medicines to market, benefiting more patients, and allowing cellular medicines to write a new chapter in life.